At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 560 target
Drug / intervention
Cadonilimab (AK104) +1 moredrug
Likely dose
Sugemalimab 1200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Consolidation Therapy of AK104 Versus Sugemalimab in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent or Sequential Chemoradiotherapy
In Brief
A Phase 3 clinical trial evaluating Cadonilimab (AK104) and Sugemalimab for NSCLC (Non-small Cell Lung Cancer). Currently recruiting, targeting 560 participants across 1 site.
Detailed Summary
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC (Non-small Cell Lung Cancer)
CountriesChina
Collaborators--
Timeline
Phase 3Recruiting
20252026202720282029
First PostedSep 2024
Enrollment StartNov 2024
TodayJul 2026
Primary CompletionOct 2026
Study CompletionDec 2028
First PostedSep 27, 2024
Enrollment StartNov 12, 2024
Primary CompletionOct 28, 2026
Study CompletionDec 30, 2028
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 1.8 years agoPrimary completion in 4 months
Interventions
Cadonilimab (AK104)drug
AK104 ivgtt Q3W
Sugemalimabdrug
1200mg Q3W